Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: a case report

Journal of Medical Case Reports

Maria Pazzaglia¹  Elisa Menegatti¹  Sebastiano Rosso¹  Maurizio Menichetti¹ 

[1] UO PS/MURG OC S. Maria delle Croci, Viale Randi 5, Ravenna, 48121, Italy

关键词: Rivaroxaban;    Pulmonary embolism;    Mortality risk;    Elderly;    Case report;    Anticoagulant;   

Others  :  1235862
DOI  :  10.1186/s13256-015-0758-6

 received in 2015-06-12, accepted in 2015-11-05,  发布年份 2015

【 摘 要 】

Introduction

Pulmonary embolism remains one of the leading causes of cardiovascular mortality. The standard treatment for pulmonary embolism is anticoagulant therapy using low molecular weight heparin, fondaparinux and a vitamin K antagonist, but a recent clinical trial showed that rivaroxaban, an oral factor Xa inhibitor, was as effective as standard therapy for the initial and long-term treatment of pulmonary embolism and had less bleeding complications.

Case presentation

The present report describes the case of an 80-year-old white man with an intermediate to low early mortality risk of pulmonary embolism. He was successfully treated with rivaroxaban (administered orally as monotherapy), demonstrating rapid benefit without any adverse events.

Conclusion

Rivaroxaban, particularly in the acute phase of pulmonary embolism, may be considered an effective and safe therapeutic choice even in elderly patients, a population less represented in clinical trials.

【 授权许可】

   
2015 Menichetti et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008; 28:370-2.
• [2]Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG et al.. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98:756-64.
• [3]Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest. 1995; 108:978-81.
• [4]Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population based case–control study. Arch Intern Med. 2000; 160:809-15.
• [5]Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E et al.. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366:1287-97.
• [6]2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35:3145-6.
• [7]Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J et al.. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005; 172:1041-6.
• [8]Jiménez D, Aujesky D, Díaz G, Monreal M, Otero R, Martí D et al.. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med. 2010; 181:983-91.
• [9]Fraga M, Taffé P, Méan M, Hugli O, Witzig S, Waeber G et al.. The inter-rater reliability of the Pulmonary Embolism Severity Index. Thromb Haemost. 2010; 104:1258-62.
• [10]Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012; 379:1835-46.
• [11]Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008; 24:2757-65.
• [12]Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78:412-21.